Published in Ther Adv Hematol on June 01, 2011
Critical appraisal of rituximab in the maintenance treatment of advanced follicular lymphoma. Cancer Manag Res (2015) 0.78
Symptom burden & quality of life among patients receiving second-line treatment of metastatic colorectal cancer. BMC Res Notes (2012) 0.78
Derivation of research diagnostic criteria for insomnia: report of an American Academy of Sleep Medicine Work Group. Sleep (2004) 6.12
First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol (2005) 2.82
Cognitive behavioral therapy for insomnia improves sleep and decreases pain in older adults with co-morbid insomnia and osteoarthritis. J Clin Sleep Med (2009) 2.05
Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol (2008) 2.05
Breast cancer, version 3.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw (2013) 1.79
The scoring of arousal in sleep: reliability, validity, and alternatives. J Clin Sleep Med (2007) 1.71
An observational study of outcomes after initial infused therapy in Medicare patients diagnosed with chronic lymphocytic leukemia. Blood (2010) 1.67
Minimal clinically important difference for the ocular surface disease index. Arch Ophthalmol (2010) 1.67
Sleep and quality of life in breast cancer patients. J Pain Symptom Manage (2002) 1.65
Breast cancer version 3.2014. J Natl Compr Canc Netw (2014) 1.63
Breast Cancer Version 2.2015. J Natl Compr Canc Netw (2015) 1.59
Small N designs for rehabilitation research. J Rehabil Res Dev (2012) 1.42
Cost-effectiveness of rituximab as maintenance therapy in patients with follicular non-Hodgkin lymphoma after responding to first-line rituximab plus chemotherapy. Leuk Lymphoma (2012) 1.40
Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2016) 1.40
Variations in the incidence of postpartum hemorrhage across hospitals in California. Matern Child Health J (2005) 1.30
Reductive processes controlling arsenic retention: revealing the relative importance of iron and arsenic reduction. Environ Sci Technol (2008) 1.24
An initial report of sleep disturbance in inactive inflammatory bowel disease. J Clin Sleep Med (2006) 1.21
Retrospective chart review of severe infusion reactions with rituximab, cetuximab, and bevacizumab in community oncology practices: assessment of clinical consequences. Support Care Cancer (2007) 1.20
The Cancer Care Monitor: psychometric content evaluation and pilot testing of a computer administered system for symptom screening and quality of life in adult cancer patients. J Pain Symptom Manage (2003) 1.16
Testing the reliability and validity of DSM-IV-TR and ICSD-2 insomnia diagnoses. Results of a multitrait-multimethod analysis. Arch Gen Psychiatry (2011) 1.13
Myeloid growth factors. J Natl Compr Canc Netw (2013) 1.13
Recent developments in the classification, evaluation, and treatment of insomnia. Chest (2006) 1.11
Health reform in action: updates on implementation of the Affordable Care Act. Obstet Gynecol (2014) 1.10
The relation of trouble sleeping, depressed mood, pain, and fatigue in patients with cancer. J Clin Sleep Med (2009) 1.09
Adherence, reports of benefits, and depression among patients treated with continuous positive airway pressure. Psychosom Med (2007) 1.07
Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC). Lung Cancer (2008) 1.06
Validation of the Cancer Care Monitor items for physical symptoms and treatment side effects using expert oncology nurse evaluation. J Pain Symptom Manage (2006) 1.04
Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab. Clin Cancer Res (2013) 1.02
Referral and treatment patterns among patients with stages III and IV non-small-cell lung cancer. J Oncol Pract (2013) 1.01
Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma. Gynecol Oncol (2012) 0.99
Circadian phase in delayed sleep phase syndrome: predictors and temporal stability across multiple assessments. Sleep (2006) 0.99
Implications of IV monoclonal antibody infusion reaction for the patient, caregiver, and practice: results of a multicenter study. Support Care Cancer (2008) 0.98
Examining maladaptive beliefs about sleep across insomnia patient groups. J Psychosom Res (2010) 0.97
Daytime sleepiness and alertness in patients with Parkinson disease. Sleep (2004) 0.96
Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States. Ann Hematol (2015) 0.96
Innovative strategies to reduce disparities in the quality of prenatal care in underresourced settings. Med Care Res Rev (2010) 0.95
The scoring of cardiac events during sleep. J Clin Sleep Med (2007) 0.94
Impact of adherence with positive airway pressure therapy on hypercapnia in obstructive sleep apnea. J Clin Sleep Med (2006) 0.90
Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma. Leuk Lymphoma (2008) 0.89
Pain coping strategies for tension-type headache: possible implications for insomnia? J Clin Sleep Med (2009) 0.89
Treatment practice in the elderly patient with chronic lymphocytic leukemia-analysis of the combined SEER and Medicare database. Ann Hematol (2014) 0.89
Hematologic outcomes and blood utilization in cancer patients with chemotherapy-induced anemia (CIA) pre- and post-national coverage determination (NCD): results from a multicenter chart review. Support Care Cancer (2011) 0.87
Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for the treatment of previously untreated chronic lymphocytic leukemia. Leuk Lymphoma (2011) 0.86
Phase 2 study of pemetrexed plus carboplatin, or pemetrexed plus cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/B non-small-cell lung cancer. J Thorac Oncol (2013) 0.84
The association of rash severity with overall survival: findings from patients receiving erlotinib for pancreatic cancer in the community setting. Pancreas (2013) 0.83
Budget impact model of adding erlotinib to a regimen of gemcitabine for the treatment of locally advanced, nonresectable or metastatic pancreatic cancer. Clin Ther (2008) 0.83
A prospective investigation of chemotherapy-induced neutropenia and quality of life. J Support Oncol (2006) 0.82
Hospital rates of maternal and neonatal infection in a low-risk population. Matern Child Health J (2005) 0.82
Symptom Burden for Patients with Metastatic Colorectal Cancer Treated with First-Line FOLFOX or FOLFIRI with and Without Bevacizumab in the Community Setting. Support Cancer Ther (2007) 0.82
Influence of patient perceptions and preferences for osteoporosis medication on adherence behavior in the Denosumab Adherence Preference Satisfaction study. Menopause (2014) 0.82
Development, reliability, and validity of a new Preference and Satisfaction Questionnaire. Value Health (2011) 0.82
Survival in elderly follicular lymphoma patients who receive frontline chemo-immunotherapy. Am J Hematol (2010) 0.82
"Real world" treatment of metastatic renal cell carcinoma in a joint community-academic cohort: progression-free survival over three lines of therapy. Clin Genitourin Cancer (2013) 0.82
Comparative effectiveness of chemotherapy in elderly patients with metastatic colorectal cancer. J Gastrointest Cancer (2013) 0.81
Validation of a patient satisfaction questionnaire for anemia treatment, the PSQ-An. Health Qual Life Outcomes (2006) 0.81
Initial treatment and changes in adjuvant endocrine therapy for early stage breast cancer. Breast (2009) 0.81
Retrospective study of the effect of disease progression on patient reported outcomes in HER-2 negative metastatic breast cancer patients. Health Qual Life Outcomes (2011) 0.80
Histopathologic and Radiologic Assessment of Chemotherapeutic Response in Ewing's Sarcoma: A Review. Sarcoma (2012) 0.80
Willingness to pay to prevent chemotherapy induced nausea and vomiting among patients with breast, lung, or colorectal cancer. J Med Econ (2013) 0.80
Relationship between incidence of fracture and health-related quality-of-life in metastatic breast cancer patients with bone metastases. J Med Econ (2012) 0.80
A phase II study of concurrent chemoradiation with weekly docetaxel, carboplatin, and radiation therapy followed by consolidation chemotherapy with docetaxel and carboplatin for locally advanced inoperable non-small cell lung cancer (NSCLC). J Thorac Oncol (2009) 0.80
Experiencing neutropenia: quality of life interviews with adult cancer patients. BMC Nurs (2005) 0.80
Clinical roundtable monograph. Treatment of chemotherapy-induced nausea and vomiting: a post-MASCC 2010 discussion. Clin Adv Hematol Oncol (2011) 0.79
Treatment patterns and outcomes among patients with metastatic melanoma treated in community practice. Int J Dermatol (2014) 0.79
Patient-specific vaccines derived from autologous tumor cell lines as active specific immunotherapy: results of exploratory phase I/II trials in patients with metastatic melanoma. Cancer Biother Radiopharm (2007) 0.79
A retrospective study of quality of life in a community sample of patients with early stage breast cancer. Breast Cancer Res Treat (2009) 0.79
Managing the toxicity of hematopoietic stem cell transplant. J Support Oncol (2004) 0.79
Economic impact of disease progression in follicular non-Hodgkin lymphoma. Leuk Lymphoma (2011) 0.78
HER2 in well differentiated breast cancer: is testing necessary? Breast Cancer Res Treat (2008) 0.78
The need for a standardized CPAP titration protocol and follow-up procedures. J Clin Sleep Med (2005) 0.78
Second- and third-line treatment of patients with non-small-cell lung cancer with erlotinib in the community setting: retrospective study of patient healthcare utilization and symptom burden. Clin Lung Cancer (2009) 0.78
Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer. Cancer Chemother Pharmacol (2015) 0.78